Cargando…
Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition
During the past decade there has been renewed interest in the use of vaccine immunotherapy for the treatment of cancer. This review focuses on HER2/neu, a tumour-associated antigen that is overexpressed in 10–40% of breast cancers and other carcinomata. Several immunogenic HER2/neu peptides recogniz...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC138708/ https://www.ncbi.nlm.nih.gov/pubmed/11737893 http://dx.doi.org/10.1186/bcr330 |
_version_ | 1782120479136415744 |
---|---|
author | Correa, Isabel Plunkett, Tim |
author_facet | Correa, Isabel Plunkett, Tim |
author_sort | Correa, Isabel |
collection | PubMed |
description | During the past decade there has been renewed interest in the use of vaccine immunotherapy for the treatment of cancer. This review focuses on HER2/neu, a tumour-associated antigen that is overexpressed in 10–40% of breast cancers and other carcinomata. Several immunogenic HER2/neu peptides recognized by T lymphocytes have been identified to be included in cancer vaccines. Some of these peptides have been assessed in clinical trials of patients with breast and ovarian cancer. Although it has been possible to detect immunological responses against the peptides in the immunized patients, no clinical responses have so far been described. Immunological tolerance to self-antigens like HER2/neu may limit the functional immune responses against them. It will be of interest to determine whether immune responses against HER2/neu epitopes can be of relevance to cancer treatment. |
format | Text |
id | pubmed-138708 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2001 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-1387082003-02-27 Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition Correa, Isabel Plunkett, Tim Breast Cancer Res Review During the past decade there has been renewed interest in the use of vaccine immunotherapy for the treatment of cancer. This review focuses on HER2/neu, a tumour-associated antigen that is overexpressed in 10–40% of breast cancers and other carcinomata. Several immunogenic HER2/neu peptides recognized by T lymphocytes have been identified to be included in cancer vaccines. Some of these peptides have been assessed in clinical trials of patients with breast and ovarian cancer. Although it has been possible to detect immunological responses against the peptides in the immunized patients, no clinical responses have so far been described. Immunological tolerance to self-antigens like HER2/neu may limit the functional immune responses against them. It will be of interest to determine whether immune responses against HER2/neu epitopes can be of relevance to cancer treatment. BioMed Central 2001 2001-09-20 /pmc/articles/PMC138708/ /pubmed/11737893 http://dx.doi.org/10.1186/bcr330 Text en Copyright © 2001 BioMed Central Ltd |
spellingShingle | Review Correa, Isabel Plunkett, Tim Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition |
title | Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition |
title_full | Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition |
title_fullStr | Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition |
title_full_unstemmed | Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition |
title_short | Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition |
title_sort | update on her-2 as a target for cancer therapy: her2/neu peptides as tumour vaccines for t cell recognition |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC138708/ https://www.ncbi.nlm.nih.gov/pubmed/11737893 http://dx.doi.org/10.1186/bcr330 |
work_keys_str_mv | AT correaisabel updateonher2asatargetforcancertherapyher2neupeptidesastumourvaccinesfortcellrecognition AT plunketttim updateonher2asatargetforcancertherapyher2neupeptidesastumourvaccinesfortcellrecognition |